Biocon Chair: AI in Clinical Trials Is the Holy Grail

Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate the company above its current top-five global ranking. Speaking on the sidelines of the Bloomberg New